Collegium Pharmaceutical Inc
NASDAQ:COLL

  • LAST PRICE
    30.8300
  • TODAY'S CHANGE (%)
    0.8700 (2.9039%)
  • Bid / Lots
    29.5100/ 33
  • Ask / Lots
    32.0000/ 4
  • Open / Previous Close
    30.1500 / 29.9600
  • Day Range
    30.1500
    31.1500
  • 52 Week Range
    25.1600
    42.2873
  • Volume
    458,904

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
COLL
Collegium Pharmaceutical Inc
966.2M
15.4x
---
ANIP
ANI Pharmaceuticals Inc
1.2B
-130.6x
-8.16%
PCRX
Pacira Biosciences Inc
810.3M
-8.1x
---
HRMY
Harmony Biosciences Holdings Inc
1.9B
16.4x
---
SNDL
SNDL Inc
525.7M
-6.7x
---
TLRY
Tilray Brands Inc
1.2B
-5.2x
---
As of 2024-11-25

Company Information

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.

Contact Information

Headquarters
100 Technology Center DrSTOUGHTON, MA, United States 02072-4710
Phone
781-713-3699
Fax
---

Executives

Chairman of the Board
Michael Heffernan
President, Chief Executive Officer, Director
Vikram Karnani
Chief Financial Officer, Executive Vice President
Colleen Tupper
Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Shirley Kuhlmann
Executive Vice President, Chief Commercial Officer
Scott Dreyer

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$966.2M
Revenue (TTM)
$599.2M
Shares Outstanding
32.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.81
EPS
$2.00
Book Value
$6.13
P/E Ratio
15.4x
Price/Sales (TTM)
1.6
Price/Cash Flow (TTM)
4.1x
Operating Margin
30.40%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.